The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary ...

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

This is the first randomized clinical trial of transcatheter aortic valve implantation (TAVI). It showed that 1-year outcomes are dramatically improved among patients who are not candidates for ...